Mankind Pharma Q1 FY27 Earnings Call Transcript: Strong Growth Led by Domestic Business and Better Margins

BY ADMIN • FILED 04 Aug 2026, 4:33 PM

Mankind Pharma Limited delivered a strong performance in the first quarter of FY27, reporting healthy revenue growth, improved profitability, and continued momentum in its domestic pharmaceutical business. During the earnings call, the management highlighted that strong execution, growth in chronic therapies, and better operating efficiency helped the company start the financial year on a positive note.

Revenue Crosses ₹4,000 Crore

For Q1 FY27, Mankind Pharma reported revenue of ₹4,031 crore, a 13% increase compared to the same quarter last year.

The company also reported an EBITDA of ₹1,060 crore, with the EBITDA margin improving to 26.3%, an increase of 250 basis points year-on-year. Management said the improvement reflects better operating leverage and disciplined cost management.

Domestic Business Remains the Key Growth Driver

Mankind’s domestic pharmaceutical business continued to perform well.

Excluding the Consumer Healthcare segment, domestic revenue increased 11% year-on-year to ₹3,180 crore. The growth was driven by:

Strong double-digit growth in the core pharmaceutical business.
Healthy performance in chronic therapies.
Continued momentum in the BSV specialty business.
Recovery in acute therapies supported by gastro, vitamins, and gynaecology products.

According to IQVIA data shared during the call, the company’s secondary sales grew 12.7%, supported by 4.7% volume growth.

Strong Focus on Chronic Therapies

Management emphasized that the Indian pharmaceutical market is gradually shifting towards chronic and specialty treatments due to changing lifestyles and increasing incidence of chronic diseases.

To benefit from this trend, Mankind Pharma has been expanding its presence in chronic therapies while strengthening its multi-specialty portfolio. The company said its focused strategy helped improve its market share in chronic therapies during the quarter.

Profitability Improves

Apart from revenue growth, profitability also improved significantly.

Higher operating efficiency and better product mix helped the company expand its EBITDA margin to 26.3%. Management believes maintaining healthy margins while investing in future growth remains a key priority.

Consumer Healthcare Business

Management discussed the Consumer Healthcare business separately, highlighting that the company continues to invest in brand building and distribution to strengthen its position in this segment. While short-term investments may impact margins, the company remains optimistic about long-term opportunities in the consumer health market.

Management Outlook

The management expressed confidence in the company’s long-term growth prospects.

Key focus areas include:

Expanding the chronic and specialty portfolio.
Increasing market share in the domestic pharmaceutical business.
Continuing investments in brands and distribution.
Improving operational efficiency.
Delivering sustainable and profitable growth.

Management believes the company’s diversified product portfolio, strong field force, and growing presence in high-growth therapy areas position it well for future growth.